Today: 3 April 2026
Rocket Lab stock jumps after Morgan Stanley upgrade as RKLB tests fresh highs

Rocket Lab stock jumps after Morgan Stanley upgrade as RKLB tests fresh highs

New York, Jan 16, 2026, 10:39 EST — Regular session

  • Rocket Lab shares jump following Morgan Stanley’s upgrade and higher price target.
  • This comes after KeyBanc downgraded the stock, citing “priced-in” catalysts.
  • Traders are eyeing updates on Neutron’s timeline alongside the upcoming earnings date window.

Shares of Rocket Lab Corp (RKLB) jumped roughly 6% on Friday following an upgrade from Morgan Stanley, signaling renewed investor faith in the space launch and satellite firm. The stock climbed 6.4% to $96.61 in morning trading. MarketBeat

The upgrade is crucial now as investors remain divided over whether Rocket Lab’s rally can sustain itself without fresh catalysts. The coming weeks could shake the stock, hinging on updates about the Neutron rocket timeline and the speed of government contract awards.

On Thursday, KeyBanc Capital Markets cut Rocket Lab’s rating to “sector weight” from “overweight,” noting that recent milestones appear priced into the stock and that the near-term risk-reward is fairly even. The firm uses “overweight” to signal expected outperformance, while “sector weight” suggests a more neutral stance. Investing.com

On Friday, Morgan Stanley flipped the script, calling space technology “Attractive” for 2026 and upgrading Rocket Lab to “overweight,” with a price target boost to $105 from $67. Analyst Kristine Liwag pointed to “higher launch cadences, new product intros, policy support & market maturation” driving the sector next year. At the time, the S&P 500 and Nasdaq dipped roughly 0.2%. Investing.com

Rocket Lab is increasingly leaning on defense and national security contracts. In December, the company secured an $816 million deal with the Space Development Agency to build 18 satellites for its Tracking Layer Tranche 3 program — a U.S. Space Force initiative targeting missile warning and tracking. Rocket Lab expects additional subsystem sales could push the total opportunity close to $1 billion. Founder and CEO Peter Beck said the company was “honored to play a role in enabling this.” SEC

Investors are watching insider moves closely in these hot momentum stocks. Director Merline Saintil sold 108,500 shares this week in two separate transactions. That included a 96,000-share transfer into an exchange fund and a 12,500-share sale under a Rule 10b5-1 trading plan, according to a Form 4 filing. SEC

The key issue remains execution. If Neutron’s launch stumbles or Rocket Lab falls short of its projected launch pace, the stock’s premium valuation compared to established aerospace rivals could come under pressure.

Rocket Lab is set to release its next earnings report near Feb. 26, per Public.com’s earnings calendar. Traders will be watching closely for a firm date and any fresh details that narrow the timeline for Neutron’s inaugural launch. public.com

Stock Market Today

  • Goodwin PLC Insiders Sell £19m in Shares, Signaling Potential Caution
    April 3, 2026, 1:32 AM EDT. Over the past year, insiders at Goodwin PLC (LON:GDWN) sold shares worth approximately UK£19 million, far exceeding their purchases of about UK£150,000. The largest sale came from Matthew Goodwin, Managing Director of Mechanical Engineering, who sold shares at around UK£190 each, significantly above the current price of UK£122. Despite this heavy insider selling, insiders still hold 9.5% of the company, valued at UK£87 million, indicating alignment with shareholders. No insider transactions occurred in the last three months. While insider selling can have various reasons, multiple significant sales may signal caution to investors. Monitoring insider activity alongside company risks remains essential for a fuller assessment of Goodwin's outlook.
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line
Previous Story

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

American Airlines stock slides as United rivalry at O’Hare sharpens — what to watch next
Next Story

American Airlines stock slides as United rivalry at O’Hare sharpens — what to watch next

Go toTop